|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0012863,
umls-concept:C0013089,
umls-concept:C0032343,
umls-concept:C0086418,
umls-concept:C0162638,
umls-concept:C0392747,
umls-concept:C0596402,
umls-concept:C0678594,
umls-concept:C0733755,
umls-concept:C1280500,
umls-concept:C1513095,
umls-concept:C1554963
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-6-15
|
|
pubmed:abstractText |
The mechanism of the cytotoxicity of anthracyclines is pleiotropic and its significance in cell growth inhibition seems to be highly specific and dependent on cell type and anthracycline drug. Resistance and the high cardiotoxicity of anthracyclines have stimulated many studies aimed at identifying critical substituents required for optimal activity. Many authors point to the fact that the double-strand breaks, the consequence of the activity of topoisomerase II poisons, and the inability of cells to repair the DNA lesions are the signal for apoptosis. The aim of this study was to define the influence of 4-demetoxy 2'-halogenated analogs with altered basicity at the 3'-position on topoisomerase II and the relationship of that interaction with apoptosis and the cytotoxicity of these novel anthracyclines. Parental human ME18 melanoma cells and the ME18/R subline, obtained experimentally, resistant to doxorubicin (DOX), exposed to 1.7 and 8.6 microM DOX or its analogs, annamycin and WP903 (both 0.3 and 3.0 microM) were studied.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-10075079,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-11145758,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-11264450,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-11396183,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-12136248,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-12684672,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-12755489,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-12792789,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-12915875,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-14499010,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-14654958,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-15253137,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-15331926,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-15486187,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-15542779,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-15957528,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-15980993,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-16158963,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-8190107,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-8385463,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-8651936,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-8996519,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-9337076,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-9744572,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17557149-9823938
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0004-069X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
55
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
193-8
|
|
pubmed:dateRevised |
2010-9-14
|
|
pubmed:meshHeading |
pubmed-meshheading:17557149-Antibiotics, Antineoplastic,
pubmed-meshheading:17557149-Apoptosis,
pubmed-meshheading:17557149-Cell Line, Tumor,
pubmed-meshheading:17557149-Cell Survival,
pubmed-meshheading:17557149-DNA Topoisomerases, Type II,
pubmed-meshheading:17557149-Doxorubicin,
pubmed-meshheading:17557149-Drug Resistance, Neoplasm,
pubmed-meshheading:17557149-Humans,
pubmed-meshheading:17557149-Melanoma
|
|
pubmed:articleTitle |
Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells.
|
|
pubmed:affiliation |
Department of Biochemistry and Biopharmaceuticals, National Institute of Medicines, Che?mska 30/34, 00-725, Warsaw, Poland. b-gruber@il.waw.pl
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
